ArticleFrontiers in public health2026
Longitudinal SARS-CoV-2 seroprevalence among learners, parents, and teachers in a South African school community.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Longitudinal assessments of SARS-CoV-2 seroprevalence among a triad of parents, teachers and children in low-middle income countries are scarce. CoKiDSS assessed changes in seroprevalence among asymptomatic primary school learners, their parents, and teachers in a semi-rural South African school setting. Methods: SARS-CoV-2 seroprevalence was estimated at baseline (May-August 2023) and follow-up (October 2023) using a point-of-care COVID-19 IgG/IgM test. Results were adjusted for test sensitivity and specificity. Between-group differences and within-participant serostatus changes were assessed using Fisher's exact test, and McNemar's test, respectively. Results: 292 participants (203 learners, 71 parents, and 18 teachers) were included in this analysis. At baseline, overall (all group combined), SARS-CoV-2 IgG seroprevalence was 73% (unadjusted) and 78% (adjusted for test sensitivity). Seropositivity was higher among learners compared to parents (74% unadjusted to 77% adjusted vs. 66% unadjusted to 69% adjusted), with teachers showing the highest levels (94% unadjusted to 99% adjusted). Approximately 2.7% of learners were IgM seropositive, while about 25% of participants were IgG/IgM seronegative (24% of learners, 34% of parents, and 5.6% of teachers). At follow-up, overall SARS-CoV-2 IgG seroprevalence rose to 85% (unadjusted) to 95% (adjusted), with increases across all groups (learners: 96%, parents: 90%, teachers: 100%). A group-level longitudinal assessment showed there were significant increases in IgG seropositivity among learners (74-90%, Discussion: Three years after the COVID-19 pandemic, despite no reported symptoms, and no vaccination campaigns, SARS-CoV-2 IgG seroprevalence increased over the 3-4-month follow-up period, particularly among unvaccinated learners, suggesting ongoing exposure and antibody persistence, although causal attribution cannot be established. Teachers maintained consistently high seroprevalence, likely reflecting sustained antibodies following prior infection or vaccination. Data suggest high levels of circulating virus and asymptomatic spread created endemicity in this environment. These findings should not guide vaccination policy but instead inform understanding of population-level seroprevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.